News
Kamada presents studies on Alpha-1 augmentation therapy, inhaled AAT for cystic fibrosis, to American Thoracic Society
SAN DIEGO, CA—Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, today announced that new, positive clinical data on its lead candidate, alpha-1 antitrypsin (“AAT”), has been presented at the annual congress of the American Thoracic Society (“ATS”), May 15 – 20, San Diego, California.
“The results presented at ATS demonstrate the efficacy and safety of our intravenous and inhaled versions of alpha-1 antitrypsin in respiratory disease,” said David Tsur, Chief Executive Officer of Kamada. “Pending regulatory processes, we hope to have our intravenous product in the US market during the course of the next year. We are also very excited about the prospects for our inhaled version of alpha-1 antitrypsin in cystic fibrosis, and other respiratory disorders, and look forward to continuing its development.”
